[Malignant melanoma].
Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S.
Pathologe. 2020 May;41(3):281-292. doi: 10.1007/s00292-020-00776-x.
[Malignant melanoma].
Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S.
Hautarzt. 2020 Jan;71(1):63-77. doi: 10.1007/s00105-019-04514-0.
Malignant melanoma.
Lang PG Jr.
Med Clin North Am. 1998 Nov;82(6):1325-58. doi: 10.1016/s0025-7125(05)70418-1.
DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
Koroknai V, Szász I, Hernandez-Vargas H, Fernandez-Jimenez N, Cuenin C, Herceg Z, Vízkeleti L, Ádány R, Ecsedi S, Balázs M.
Exp Dermatol. 2020 Jan;29(1):39-50. doi: 10.1111/exd.14047. Epub 2019 Nov 14.
Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
Li CY, Wang Q, Wang X, Li G, Shen S, Wei X.
Eur J Pharmacol. 2019 Sep 5;858:172463. doi: 10.1016/j.ejphar.2019.172463. Epub 2019 Jun 15.
Thin melanoma.
Elder DE.
Arch Pathol Lab Med. 2011 Mar;135(3):342-6. doi: 10.5858/2009-0479-RA.1.
Metabolic reprogramming supports the invasive phenotype in malignant melanoma.
Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L.
Cancer Lett. 2015 Sep 28;366(1):71-83. doi: 10.1016/j.canlet.2015.06.006. Epub 2015 Jun 18.
Desmoplastic malignant melanoma.
Frolow GR, Shapiro L, Brownstein MH.
Arch Dermatol. 1975 Jun;111(6):753-4.
[Genomic alterations of invasive melanoma cells].
Koroknai V.
Magy Onkol. 2022 Oct 5;66(3):243-245. Epub 2022 Aug 22.
Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type.
Tannous ZS, Lerner LH, Duncan LM, Mihm MC Jr, Flotte TJ.
Hum Pathol. 2000 Jun;31(6):705-8. doi: 10.1053/hupa.2000.7640.
